Freedom Finance and Binance Join Forces in Digital Assets 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Irvine, CA, May 03, 2018 -- TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ending on March 31, 2018.
For the quarter ended March 31, 2018, Trimedyne had revenues of $1,352,000, an increase of 21% from revenues of $1,119,000 for the prior year quarter. We had a net income for the current quarter of $24,000 or $0.20 per share, as compared to a net loss of $31,000 or $(0.25) per share for the prior year quarter. The net income during the current quarter as compared to a net loss during the prior year quarter is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of our cost controls.
For the six-month period ended March 31, 2018, Trimedyne had revenues of $2,886,000, an increase of 30% from revenues of $2,213,000 for the prior year six-month period. We had net income for the current six-month period of $110,000 or $0.90 per share, as compared to a net loss of $256,000 or $(2.09) per share for the prior year six-month period. The net income during the current six-month period as compared to a net loss during the prior year six-month period is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of our cost controls.
Commenting on the financial results for the quarter, Marvin P. Loeb, Sc.D., Chairman of Trimedyne, said: “Since we are no longer required to file periodic reports with the SEC, our Financial Statements are un-audited. However, we believe our Financial Statements have been prepared and contain all adjustments of a recurring nature that are necessary for a fair presentation of our operations and financial condition for the periods and dates shown.”
“We appreciate the patience of our shareholders, and we are working hard to improve our financial condition.”
If you would like a copy of the financial statements, please send an email to [email protected], and we will be happy to send it to you.
CONTACT: Jeffrey Rudner (949) 951-3800, Ext. 285 [email protected]
